CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

(2012) M. P. Goetz et al.   CLINICAL CANCER RESEARCH

Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters

(2012) Hiltrud Brauch et al.   JOURNAL OF CLINICAL ONCOLOGY

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Y. Nakamura et al.   JNCI-Journal of the National Cancer Institute

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) V. Stanton   JNCI-Journal of the National Cancer Institute

CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

(2012) James M. Rae et al.   JNCI-Journal of the National Cancer Institute

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Meredith M. Regan et al.   JNCI-Journal of the National Cancer Institute

Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial

(2012) Benjamin French et al.   Trials

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

(2011) T E Mürdter et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

(2011) William J. Irvin et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

(2010) Alastair M. Thompson et al.   BREAST CANCER RESEARCH AND TREATMENT

CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification

(2010) W. Schroth et al.   CLINICAL CANCER RESEARCH

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

(2009) Werner Schroth   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

(2009) J M Rae et al.   PHARMACOGENOMICS JOURNAL

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

(2008) Ulrich M. Zanger et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer

(2008) L. W. M. Loo et al.   GENES CHROMOSOMES & CANCER